Otsuka Corporation (OSUKF)
OTCMKTS · Delayed Price · Currency is USD
20.77
0.00 (0.00%)
Feb 11, 2026, 4:00 PM EST
Otsuka Revenue
In the year 2025, Otsuka had annual revenue of 1.32T JPY with 19.42% growth. Otsuka had revenue of 317.07B in the quarter ending December 31, 2025, with 11.10% growth.
Revenue
1.32T JPY
Revenue Growth
+19.42%
P/S Ratio
0.91
Revenue / Employee
136.65M JPY
Employees
9,680
Market Cap
7.68B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.32T | 215.12B | 19.42% |
| Dec 31, 2024 | 1.11T | 130.30B | 13.33% |
| Dec 31, 2023 | 977.37B | 116.35B | 13.51% |
| Dec 31, 2022 | 861.02B | 9.13B | 1.07% |
| Dec 31, 2021 | 851.89B | 15.57B | 1.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EACO Corporation | 444.96M |
| SED International Holdings | 232.49M |
| Jaco Electronics | 191.64M |
| Netlist | 147.19M |
| Paragon Technologies | 143.86M |
| ADDvantage Technologies Group | 56.70M |
| Surge Components | 35.26M |
| Taitron Components | 3.55M |
Otsuka News
- 21 days ago - EU Approves DAWNZERA For Hereditary Angioedema, Says Ionis And Otsuka - Nasdaq
- 4 weeks ago - LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Otsuka Corp (4768) - GuruFocus
- 7 weeks ago - 4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop - Seeking Alpha
- 7 weeks ago - Otsuka Initiates Global Phase 3 Trial Of Repinatrabit For Phenylketonuria - Nasdaq
- 2 months ago - FDA Approves Otsuka's (OTSKF) Voyxact for IgAN Treatment - GuruFocus
- 2 months ago - Otsuka gains FDA approval for sibeprenlimab for proteinuria reduction - Seeking Alpha
- 2 months ago - FDA Grants Accelerated Approval For Otsuka's VOYXACT In IgAN - Nasdaq